Codelivery of siRNA and a cisplatin prodrug [Engineering]

Cisplatin and other DNA-damaging chemotherapeutics are widely used to treat a broad spectrum of malignancies. However, their application is limited by both intrinsic and acquired chemoresistance. Most mutations that result from DNA damage are the consequence of error-prone translesion DNA synthesis, which could be responsible for the acquired resistance against...

Source: Proceedings of the National Academy of Sciences - November 12, 2013 Category: Science Authors: Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., Langer, R., Walker, G. C., Farokhzad, O. C. Tags: Biological Sciences Source Type: research